Search

Your search keyword '"Abildgaard Niels"' showing total 975 results

Search Constraints

Start Over You searched for: Author "Abildgaard Niels" Remove constraint Author: "Abildgaard Niels"
975 results on '"Abildgaard Niels"'

Search Results

2. Relationship between reasons for intermittent missing patient-reported outcomes data and missing data mechanisms

4. Health-related quality of life and quality-adjusted progression free survival for carfilzomib and dexamethasone maintenance following salvage autologous stem-cell transplantation in patients with multiple myeloma: a randomized phase 2 trial by the Nordic Myeloma Study Group

9. No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma

12. A polygenic risk score for multiple myeloma risk prediction

13. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

14. Exercise in newly diagnosed patients with multiple myeloma: A randomized controlled trial of effects on physical function, physical activity, lean body mass, bone mineral density, pain, and quality of life.

15. Limited Evidence for the Benefits of Exercise in Older Adults with Hematological Malignancies: A Systematic Review and Meta-Analysis.

18. COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network

19. Strategies to improve patient-reported outcome completion rates in longitudinal studies

21. Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group

24. Treatment of the elderly patient with haematological cancer

25. Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network

27. Comparison of 18F-sodium fluoride uptake in the whole bone, pelvis, and femoral neck of multiple myeloma patients before and after high-dose therapy and conventional-dose chemotherapy

28. Author Correction: Germline variants at SOHLH2 influence multiple myeloma risk

29. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

30. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

31. Novel Developments in the Treatment of Multiple Myeloma-Associated Bone Disease

33. Toward Cytogenomics

34. OA-10 Four years treatment with zoledronic acid is superior to two years in protection against progressive bone disease in multiple myeloma

35. P-277 Venetoclax versus bortezomib, in combination with daratumumab and dexamethasone, in patients with t(11;14)-positive relapsed or refractory multiple myeloma

37. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study

38. Genetically determined telomere length and multiple myeloma risk and outcome

39. Germline variants at SOHLH2 influence multiple myeloma risk

43. Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13

45. P919: TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WITH ZOLEDRONIC ACID FOR FOUR YEARS INSTEAD OF TWO YEARS DECREASES RISK OF PROGRESSIVE BONE DISEASE WITHOUT INCREASING RISK OF OSTEONECROSIS OF THE JAW.

47. P1671: CARFILZOMIB-DEXAMETHASONE MAINTENANCE HAMPERS RECOVERY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA

48. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

Catalog

Books, media, physical & digital resources